CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: Diagnostic and prognostic impact

American Journal of Surgical Pathology

Volumn 37, Issue 12, 2013, Pages 1845-1854

  Jullié, Marie Laure ^a   Carlotti, Martina ^a   Vivot, Alexandre ^a   Beylot Barry, Marie ^a   Ortonne, Nicolas ^b   Frouin, Eric ^c   Carlotti, Agnes ^d   De Muret, Anne ^e   Balme, Brigitte ^f   Franck, Frédéric ^g   Merlio, Jean Philippe ^a   Vergier, Béatrice ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b Paris Est University   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

aberrant expression; inflammatory infiltrate; prognosis; transformed mycosis fungoides

Indexed keywords

EID: 84888132899     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000091     Document Type: Article

References (34)

1. Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: A retrospective analysis of 100 cases. Blood. 2012;119:1643-1649
2. Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: Clinical characteristics and prognosis. Blood. 1998;92:1150-1159
3. Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol. 1988;132:265-277
4. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: Validation of the revised International Society for Cutaneous Lymphomas/ European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730-4739
5. Dmitrovsky E, Matthews MJ, Bunn PA, et al. Cytologic transformation in cutaneous T cell lymphoma: A clinicopathologic entity associated with poor prognosis. J Clin Oncol. 1987;5:208-215
6. Barberio E, Thomas L, Skowron F, et al. Transformed mycosis fungoides: Clinicopathological features and outcome. Br J Dermatol. 2007;157:284-289
7. Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: Clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood. 2000; 95:2212-2218
8. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255-266
9. Warzynski MJ, Graham DM, Axtell RA, et al. Low level CD20 expression on T cell malignancies. Cytometry. 1994;18:88-92
10. Huang Y, Moreau A, Dupuis J, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol. 2009;33:682-690
11. Dubus P, Labouyrie E, Bilhou-Nabera C, et al. Study of B-lymphocyte clonality using in vitro gene amplification (PCR) in paraffin embedded samples. Ann Pathol. 1994;14:227-233
12. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317
13. Beylot-Barry M, Sibaud V, Thiebaut R, et al. Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol. 2001;117:920-926
14. Sen F, Kang S, Cangiarella J, et al. CD20 positive mycosis fungoides: A case report. J Cutan Pathol. 2008;35:398-403
15. Blakolmer K, Vesely M, Kummer JA, et al. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas. Mod Pathol. 2000;13: 766-772
16. Balmer NN, Hughey L, Busam KJ, et al. Primary cutaneous peripheral T-cell lymphoma with aberrant coexpression of CD20: Case report and review of the literature. Am J Dermatopathol. 2009;31:187-192
17. Rahemtullah A, Longtine JA, Harris NL, et al. CD20+ T-cell lymphoma: Clinicopathologic analysis of 9 cases and a review of the literature. Am J Surg Pathol. 2008;32:1593-1607
18. Garcia-Herrera A, Colomo L, Camos M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: A heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol. 2008;26:3364-3371
19. Tachibana T, Tomita N, FuruyaM, et al. Aberrant CD20 expression in angioimmunoblastic T-cell lymphoma. Intern Med. 2011;50:495-499
20. Hultin LE, Hausner MA, Hultin PM, et al. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14:196-204
21. Quintanilla-Martinez L, Preffer F, Rubin D, et al. CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol. 1994;102:483-489
22. Murayama Y, Mukai R, Sata T, et al. Transient expression of CD20 antigen (pan B cell marker) in activated lymph node T cells. Microbiol Immunol. 1996;40:467-471
23. Magro CM, Seilstad KH, Porcu P, et al. Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. Am J Clin Pathol. 2006;126:14-22
24. Hirata Y, Yokote T, Kobayashi K, et al. Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified. Leuk Res. 2009;33:e13-e16
25. Barzilai A, Trau H, David M, et al. Mycosis fungoides associated with B-cell malignancies. Br J Dermatol. 2006;155:379-386
26. Huwait H, Wang B, Shustik C, et al. Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Am J Dermatopathol. 2010;32:65-70
27. Hull PR, Saxena A. Mycosis fungoides and chronic lymphocytic leukaemia - Composite T-cell and B-cell lymphomas presenting in the skin. Br J Dermatol. 2000;143:439-444
28. Kaleem Z, McGuire MH, Caracioni AC, et al. Composite B-cell and T-cell non-Hodgkin lymphoma of the tibia. Am J Clin Pathol. 2005; 123:215-221
29. Yang SF, Chang WY, Lan CC, et al. Composite primary cutaneous peripheral T-cell lymphoma and Epstein-Barr virus-positive large B-cell lymphoma. Leuk Lymphoma. 2011;52:2027-2030
30. Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33:81-90
31. Battistella M, Beylot-Barry M, Bachelez H, et al. Primary cutaneous follicular helper T-cell lymphoma: A new subtype of cutaneous T-cell lymphoma reported in a series of 5 cases. Arch Dermatol. 2012;148: 832-839
32. Ohmatsu H, Sugaya M, Kadono T, et al. CXCL13 and CCL21 are expressed in ectopic lymphoid follicles in cutaneous lymphoproliferative disorders. J Invest Dermatol. 2007;127:2466-2468
33. Mullegger RR, Means TK, Shin JJ, et al. Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: Predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma. Infect Immun. 2007;75:4621-4628
34. Cetinozman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol. 2012;36:109-116